Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug

1. A sustained-release oral pharmaceutical composition comprising within a single dosage form:

a hydrophilic matrix comprising a cellulose ether selected from the group consisting of a hydroxyalkyl cellulose, a carboxyalkyl cellulose, and a combination thereof;

a therapeutically effective amount of a non-opioid amine-containing compound; and

a salt of a non-steroidal anti-inflammatory drug (NSAID);

wherein the non-opioid amine-containing compound and the salt of an NSAID are within the hydrophilic matrix; and

wherein the composition exhibits a release profile with respect to the non-opioid amine-containing compound, wherein the release profile comprises a substantial portion that is representative of zero-order release kinetics under in vitro conditions as a result of dissolution of the hydrophilic matrix.

2. The composition of claim 1 , wherein cellulose ether comprises hydroxypropyl methylcellulose.

3. The composition of claim 1 , further comprising microcrystalline cellulose.

4. The composition of claim 1 , wherein the non-opioid amine-containing compound comprises a tertiary amine.

5. The composition of claim 1 , wherein the non-opioid amine-containing compound is selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, baclofen, arbaclofen, ritodrine, tizanidine, flurazepam, chlorpheniramine, doxylamine, diphenhydramine, diltiazem, rimantadine, amantadine, memantine, and combinations thereof.

6. The composition of claim 1 , wherein the non-opioid amine-containing compound is a salt comprising a hydrochloride, a bitartrate, an acetate, a naphthylate, a tosylate, a mesylate, a besylate, a succinate, a palmitate, a stearate, an oleate, a pamoate, a laurate, a valerate, a hydrobromide, a sulfate, a methane sulfonate, a tartrate, a citrate, a maleate, or a combination of the foregoing.

7. The composition of claim 1 , wherein the NSAID salt is selected from the group consisting of a salicylate derivative, a 2-aryl propionic acid derivative, a pyrazolidine derivative, an N-arylanthranilic acid derivative, an oxicam derivative, an arylalkanoic acid, an indole derivative, and combinations thereof.

8. The composition of claim 1 , wherein the NSAID salt is present in an amount effective to provide zero-order release kinetics of the non-opioid amine-containing compound from the hydrophilic matrix under in vitro conditions.

9. The composition of claim 1 , further comprising a pharmaceutically acceptable anionic surfactant, wherein the non-opioid amine-containing compound, the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.

10. The composition of claim 9 , wherein the pharmaceutically acceptable anionic surfactant is selected from the group consisting of monovalent alkyl carboxylates, acyl lactylates, alkyl ether carboxylates, N-acyl sarcosinates, polyvalent alkyl carbonates, N-acyl glutamates, fatty acid-polypeptide condensates, sulfur-containing surfactants, phosphated ethoxylated alcohols, and combinations thereof.

11. The composition of claim 9 , wherein the pharmaceutically acceptable anionic surfactant is present in an amount effective to modify the rate of release of the non-opioid amine-containing compound from the hydrophilic matrix.

12. The composition of claim 1 , wherein the single dosage form is a tablet form.

13. A sustained-release oral pharmaceutical composition comprising within a single dosage form:

a hydrophilic matrix comprising a cellulose ether;

a therapeutically effective amount of an amine-containing compound selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, ritodrine, memantine, amantadine, salts thereof, and combinations thereof; and

a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, diclofenac, ibuprofen, and combinations thereof;

wherein the amine-containing compound and the salt of an NSAID are within the hydrophilic matrix; and

wherein the composition exhibits a release profile of the amine-containing compound, wherein the release profile comprises a substantial portion that is representative of zero-order release kinetics under in vitro conditions.

14. The composition of claim 13 , wherein the cellulose ether comprises a hydroxyalkyl cellulose, a carboxyalkyl cellulose, or a combination thereof.

15. The composition of claim 13 , wherein cellulose ether comprises hydroxypropyl methylcellulose.

16. The composition of claim 13 , further comprising microcrystalline cellulose.

17. A sustained-release oral pharmaceutical composition comprising within a single dosage form:

a hydrophilic matrix comprising a cellulose ether selected from the group consisting of a hydroxyalkyl cellulose, a carboxyalkyl cellulose, and a combination thereof;

a therapeutically effective amount of an amine-containing compound selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, ritodrine, memantine, amantadine, salts thereof, and combinations thereof;

a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, diclofenac, ibuprofen, and combinations thereof; and

a pharmaceutically acceptable anionic surfactant selected from the group consisting of sodium lauryl sulfate, docusate sodium, docusate calcium, and combinations thereof;

wherein the amine-containing compound, the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix; and

wherein the composition exhibits a release profile of the amine-containing compound, wherein the release profile comprises a substantial portion that is representative of zero-order release kinetics under in vitro conditions.

18. The composition of claim 17 , wherein cellulose ether comprises hydroxypropyl methylcellulose.

19. The composition of claim 17 , further comprising microcrystalline cellulose.